• "[Normally,] a company comes together and develops things for several years and makes it to the doorstep of venture capitalists and things go on from there. This is a quite different model."

–James Campbell of InterWest Partners, on how Amplimmune Inc. was formed by partnering with academia

• "The high number and magnitude of 'persistent' ALT elevations . . . may continue to be a concern since liver toxicity is the number one safety reason why drugs fail."

–Leerink Swann analyst Joseph Schwartz breaking down Phase III mipomersen data

• "Obviously we have a number of milestones [to meet] between now and then, but we're putting 150 percent of our resources behind making it happen."

–Francois Nader, president and CEO of NPS Pharmaceuticals Inc., talking about the possibility of having two products on the market by 2013